

## Cirrhotic

**TABLE 104: SVR GENOTYPE 1 CIRRHOTIC TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + LDV12	PR48	4.31 (2.45 to 6.85)	57.01 (26.60 to 75.98)
SOF24 + LDV24		4.50 (1.60 to 7.22)	61.40 (10.41 to 81.09)
SOF12 + LDV12 + RBV12		4.63 (2.93 to 7.01)	62.08 (38.75 to 76.65)
SOF24 + LDV24 + RBV24		5.29 (3.22 to 7.90)	74.37 (42.60 to 84.52)
T12 PR48 q8		3.03 (1.36 to 5.43)	34.75 (6.55 to 63.32)
SIM12 PR24-48 RGT		3.56 (1.61 to 6.09)	44.10 (10.50 to 69.79)
SIM12 PR48		2.71 (0.89 to 5.32)	29.31 (-1.87 to 63.33)
B32 PR36-48 RGT		2.52 (0.71 to 5.62)	25.97 (-5.54 to 63.17)
DCV24 + ASU24		5.06 (3.12 to 7.65)	69.98 (41.09 to 82.16)
DCV24 + ASU24 + PR24		5.35 (3.73 to 7.80)	74.30 (56.27 to 83.06)
SIM12 + SOF12		4.67 (1.80 to 7.16)	64.69 (13.84 to 82.30)
SOF12 + SIM12 + RBV12		4.57 (1.87 to 7.23)	62.63 (14.93 to 82.28)
SOF12 + PR12		2.94 (0.32 to 6.24)	33.13 (-11.47 to 77.06)
SOF24 + LDV24	SOF12 + LDV12	1.04 (0.42 to 1.71)	3.15 (-43.40 to 35.62)
SOF12 + LDV12 + RBV12		1.06 (0.80 to 1.66)	4.42 (-15.66 to 31.18)
SOF24 + LDV24 + RBV24		1.20 (0.85 to 1.96)	15.17 (-11.25 to 44.21)
T12 PR48 q8		0.70 (0.30 to 1.39)	-21.92 (-58.37 to 19.60)
SIM12 PR24-48 RGT		0.83 (0.36 to 1.58)	-12.43 (-52.74 to 27.79)
SIM12 PR48		0.63 (0.20 to 1.37)	-27.28 (-65.97 to 19.02)
B32 PR36-48 RGT		0.59 (0.19 to 1.22)	-29.93 (-64.65 to 12.32)
DCV24 + ASU24		1.15 (0.83 to 1.91)	11.37 (-13.72 to 41.46)
DCV24 + ASU24 + PR24		1.22 (0.90 to 2.10)	16.58 (-8.45 to 48.43)
SIM12 + SOF12		1.09 (0.41 to 1.92)	7.23 (-47.92 to 42.66)
SOF12 + SIM12 + RBV12		1.07 (0.41 to 1.86)	5.26 (-46.35 to 41.22)
SOF12 + PR12		0.70 (0.07 to 1.60)	-21.85 (-74.89 to 31.08)
SOF12 + LDV12 + RBV12	SOF24 + LDV24	1.01 (0.76 to 2.61)	0.94 (-20.98 to 45.04)
SOF24 + LDV24 + RBV24		1.14 (0.76 to 3.17)	11.37 (-20.83 to 60.68)
T12 PR48 q8		0.68 (0.29 to 2.06)	-24.59 (-63.23 to 32.63)
SIM12 PR24-48 RGT		0.81 (0.35 to 2.28)	-15.37 (-57.10 to 39.04)
SIM12 PR48		0.62 (0.19 to 1.93)	-29.81 (-71.12 to 29.87)
B32 PR36-48 RGT		0.58 (0.18 to 1.61)	-31.94 (-72.29 to 20.65)
DCV24 + ASU24		1.10 (0.77 to 2.93)	7.65 (-19.69 to 55.20)
DCV24 + ASU24 + PR24		1.16 (0.85 to 3.27)	12.21 (-14.01 to 63.49)
SIM12 + SOF12		1.03 (0.41 to 2.85)	2.60 (-50.11 to 55.80)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + SIM12 + RBV12		1.02 (0.40 to 2.72)	1.32 (-52.12 to 52.81)
SOF12 + PR12		0.68 (0.07 to 2.11)	-23.92 (-80.51 to 41.53)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.13 (0.80 to 1.54)	10.61 (-16.19 to 32.49)
T12 PR48 q8		0.66 (0.29 to 1.16)	-26.70 (-60.26 to 10.33)
SIM12 PR24-48 RGT		0.78 (0.34 to 1.28)	-17.28 (-55.36 to 17.19)
SIM12 PR48		0.59 (0.19 to 1.15)	-32.37 (-68.15 to 9.47)
B32 PR36-48 RGT		0.55 (0.18 to 1.02)	-34.99 (-66.13 to 1.56)
DCV24 + ASU24		1.09 (0.83 to 1.40)	7.33 (-13.20 to 24.67)
DCV24 + ASU24 + PR24		1.15 (0.88 to 1.62)	11.71 (-10.89 to 35.72)
SIM12 + SOF12		1.03 (0.39 to 1.52)	2.26 (-50.21 to 31.91)
SOF12 + SIM12 + RBV12		1.01 (0.39 to 1.51)	0.63 (-50.50 to 30.78)
SOF12 + PR12		0.65 (0.07 to 1.32)	-27.58 (-77.85 to 21.29)
T12 PR48 q8	SOF24 + LDV24 + RBV24	0.58 (0.26 to 1.04)	-37.55 (-69.34 to 2.52)
SIM12 PR24-48 RGT		0.69 (0.31 to 1.16)	-28.35 (-64.94 to 10.48)
SIM12 PR48		0.52 (0.17 to 1.01)	-42.78 (-77.90 to 0.69)
B32 PR36-48 RGT		0.48 (0.16 to 0.93)	-46.10 (-77.94 to -5.26)
DCV24 + ASU24		0.96 (0.69 to 1.38)	-3.80 (-28.60 to 24.18)
DCV24 + ASU24 + PR24		1.00 (0.79 to 1.51)	0.02 (-19.53 to 31.10)
SIM12 + SOF12		0.90 (0.35 to 1.42)	-8.99 (-60.32 to 27.20)
SOF12 + SIM12 + RBV12		0.89 (0.35 to 1.35)	-9.60 (-60.43 to 22.88)
SOF12 + PR12		0.56 (0.06 to 1.23)	-38.88 (-87.65 to 16.09)
SIM12 PR24-48 RGT	T12 PR48 q8	1.17 (0.47 to 2.79)	8.80 (-35.12 to 48.94)
SIM12 PR48		0.90 (0.47 to 1.35)	-5.05 (-25.33 to 15.00)
B32 PR36-48 RGT		0.84 (0.22 to 2.42)	-8.41 (-54.20 to 40.49)
DCV24 + ASU24		1.64 (0.93 to 3.76)	33.73 (-5.08 to 67.33)
DCV24 + ASU24 + PR24		1.74 (1.09 to 3.83)	38.48 (6.64 to 68.73)
SIM12 + SOF12		1.51 (0.54 to 3.57)	27.29 (-29.18 to 65.87)
SOF12 + SIM12 + RBV12		1.47 (0.55 to 3.51)	25.49 (-28.77 to 64.80)
SOF12 + PR12		0.97 (0.10 to 2.80)	-1.50 (-57.77 to 53.39)
SIM12 PR48	SIM12 PR24-48 RGT	0.77 (0.24 to 2.05)	-14.28 (-56.57 to 34.07)
B32 PR36-48 RGT		0.71 (0.20 to 2.03)	-17.58 (-60.56 to 34.77)
DCV24 + ASU24		1.39 (0.84 to 3.14)	24.42 (-12.16 to 61.83)
DCV24 + ASU24 + PR24		1.48 (0.99 to 3.26)	29.41 (-0.59 to 64.19)
SIM12 + SOF12		1.29 (0.48 to 2.98)	18.40 (-36.64 to 59.17)
SOF12 + SIM12 + RBV12		1.27 (0.49 to 2.85)	17.14 (-36.22 to 58.05)
SOF12 + PR12		0.84 (0.09 to 2.38)	-9.82 (-65.71 to 47.02)
B32 PR36-48 RGT	SIM12 PR48	0.94 (0.24 to 3.48)	-2.62 (-53.39 to 47.54)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV24 + ASU24		1.84 (0.95 to 5.80)	39.00 (-3.82 to 75.35)
DCV24 + ASU24 + PR24		1.95 (1.09 to 5.94)	44.06 (7.04 to 76.86)
SIM12 + SOF12		1.67 (0.59 to 5.41)	31.99 (-26.17 to 73.59)
SOF12 + SIM12 + RBV12		1.64 (0.58 to 5.32)	30.37 (-26.60 to 72.65)
SOF12 + PR12		1.06 (0.11 to 4.05)	2.83 (-56.57 to 61.48)
DCV24 + ASU24	B32 PR36-48 RGT	1.98 (1.14 to 5.86)	42.10 (9.81 to 72.56)
DCV24 + ASU24 + PR24		2.11 (1.09 to 6.80)	47.78 (6.84 to 79.78)
SIM12 + SOF12		1.81 (0.59 to 6.27)	35.84 (-25.73 to 77.75)
SOF12 + SIM12 + RBV12		1.80 (0.61 to 5.92)	35.06 (-24.17 to 74.76)
SOF12 + PR12		1.14 (0.11 to 5.04)	6.16 (-55.13 to 68.83)
DCV24 + ASU24 + PR24	DCV24 + ASU24	1.05 (0.81 to 1.56)	4.11 (-17.22 to 33.18)
SIM12 + SOF12		0.95 (0.36 to 1.44)	-4.50 (-57.15 to 27.44)
SOF12 + SIM12 + RBV12		0.92 (0.36 to 1.41)	-6.56 (-56.58 to 26.11)
SOF12 + PR12		0.59 (0.06 to 1.19)	-34.47 (-84.90 to 13.80)
SIM12 + SOF12	DCV24 + ASU24 + PR24	0.90 (0.34 to 1.19)	-8.72 (-60.58 to 14.92)
SOF12 + SIM12 + RBV12		0.88 (0.35 to 1.17)	-10.72 (-60.35 to 13.59)
SOF12 + PR12		0.56 (0.06 to 1.08)	-39.75 (-86.66 to 6.91)
SOF12 + SIM12 + RBV12	SIM12 + SOF12	0.98 (0.42 to 2.37)	-1.75 (-49.14 to 49.06)
SOF12 + PR12		0.65 (0.12 to 1.03)	-25.62 (-63.07 to 2.04)
SOF12 + PR12	SOF12 + SIM12 + RBV12	0.67 (0.08 to 1.73)	-24.69 (-82.10 to 32.92)
Random effect model	Residual deviance	29.34 vs. 31 data points	
	Deviance information criteria	145.523	
Fixed effect model	Residual deviance	29.3 vs. 31 data points	
	Deviance information criteria	145.001	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.